Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial

PURPOSE: Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among patients with high-risk prostate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Rosenthal, Seth A., Hu, Chen, Sartor, Oliver, Gomella, Leonard G., Amin, Mahul B., Purdy, James, Michalski, Jeff M., Garzotto, Mark G., Pervez, Nadeem, Balogh, Alexander G., Rodrigues, George B., Souhami, Luis, Reaume, M. Neil, Williams, Scott G., Hannan, Raquibul, Horwitz, Eric M., Raben, Adam, Peters, Christopher A., Feng, Felix Y., Shipley, William U., Sandler, Howard M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
RAPID COMMUNICATION
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506419/
https://ncbi.nlm.nih.gov/pubmed/30860948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02158
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars